District Court Invalidates Claims Drawn To Isolated DNA As Claiming Unpatentable Subject Matter Under Section 101


On March 29, 2010, the U.S. District Court for the Southern District of New York issued a decision in Association for Molecular Pathology v. U.S. Patent and Trademark Office, No. 09 Civ.4515 (S.D.N.Y 2010), holding that several claims in patents drawn to isolated DNA sequences encoding the BRCA1 and BRCA2 genes, and methods of using those sequences to detect or screen for cancer, are invalid because the claims were not drawn to statutory subject matter under 35 U.S.C. §101. Although this decision has drawn a great deal of press, upon closer inspection, it should not affect well-counseled diagnostics companies.

Several particulars regarding this decision render it of limited importance. First, this decision was issued by a district court and, as such, is not binding precedent on either the U.S. Patent and Trademark Office (PTO) or any other court in the U.S. outside of the Southern District of New York. Additionally, of the claims invalidated, those drawn to isolated DNA are not relied upon by most diagnostics companies. Similarly, the method claims invalidated in this decision do not recite any machine, apparatus, or transformative step—limitations that post- Bilski claims typically contain. Furthermore, decisions by courts of appeal are likely to curtail the holding or modify the legal underpinnings of the decision. Therefore, in light of the limited precedential effect of this decision, the limited relevance of the claims that were invalidated, and the lengthy appeal process that will almost certainly follow this decision, diagnostics companies will typically be in the same legal position they were prior to this decision.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wilson Sonsini Goodrich & Rosati | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.